XEPLION 25 mg, suspension injectable à libération prolongée

Product identity

At a glance

Authorisation holder

JANSSEN CILAG INTERNATIONAL NV

Authorisation status

Autorisation active

Market status

Commercialisée

Country

France

Source reference

CIS 68716209

Reported market status does not confirm current pharmacy stock.

From the official composition record

Ingredients & strength

Source entries are shown individually. An active substance (SA) and its reference moiety (FT) may describe the same ingredient; do not add their strengths together.

Pack references

Presentations (1)

From the French medicines authority

Official documents

The official product entry provides access to the patient leaflet and professional product information when available. Documents are in French and availability varies by medicine.

Check the medicine name, strength and form against your pack. The authority’s current documents may be newer than the catalogue snapshot shown here.

Explore the directory

Related information

Browse published records containing these source ingredients. A shared ingredient does not establish the same strength, form, route or suitability as a substitute.

• PALIPÉRIDONE →
• PALMITATE DE PALIPÉRIDONE →

Where this information comes from

Sources & dates

Base de données publique des médicaments (BDPM), France. Retrieval dates record when we obtained the source files; they are not clinical review dates or a guarantee of current stock.

Directory source checks cover the factual catalogue record.Molindra clinical guidance has not yet been reviewed or published for this medicine.